Publication | Closed Access

Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours

Breast OncologyPatient Selection BiomarkerMedicineImmunologyBrca1 Antibody Ms110PathologyOvarian TumoursCancer GenomicsImmune Checkpoint InhibitorBreast CancerOncologyTumor BiologyEndocrine-related CancerOvarian Cancer